Sample Collection Study in Patients With Suspected Melanoma Utilizing DermTech’s Non-invasive Adhesive Patch Biopsy Kits

Overview

A multi-center sample collection study in patients presenting with pigmented lesion(s) suspicious for melanoma. All suspicious lesions should meet at least one of the "ABCDE" criteria.

Full Title of Study: “A Multi-center Sample Collection Study in Patients With Suspected Melanoma Utilizing DermTech’s Non-invasive Adhesive Patch Biopsy Kits”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: September 15, 2022

Detailed Description

A multi-center sample collection study in patients presenting with pigmented lesion(s) suspicious for melanoma. All suspicious lesions should meet at least one of the "ABCDE" (asymmetry, border, color, diameter, evolving) criteria. Patients will be consented for the study and screened against the inclusion and exclusion criteria. Once the patient is determined to be acceptable for the study they will be assigned a unique patient number and tissue collection will begin. Tissue from the lesion will be collected using DermTech's non-invasive adhesive patch kit according to the instructions for use followed by surgical biopsy. Digital dermoscopy of the lesion is preferred but not required.

Clinical Trial Outcome Measures

Primary Measures

  • Up to 1000 samples will be compared for gene expression analysis results compared to biopsy findings.
    • Time Frame: Samples will be extracted and analyzed once up to 1000 samples have been collected and compared to surgical biopsy reports. Analysis results are expected in 2021
    • gene expression associated with melanoma vs non-melanoma compared to surgical biopsy
  • Up to 1000 samples will be compared to biopsy results for DNA mutations
    • Time Frame: Samples will be extracted and analyzed once up to 1000 samples have been collected and compared to surgical reports and DNA mutation analysis. Analysis results are expected in 2021
    • Dna mutations associated with more aggressive forms of melanoma

Participating in This Clinical Trial

Inclusion Criteria

1. Males and females at least 21 years of age

2. Have a pigmented lesion suspicious for melanoma the pigmented lesion meets at least one of the "ABCDE" criteria

3. The pigmented lesion mst be at least 3mm and not more than 16mm in diameter

4. Patient is willing to follow the start of care to test and treat the pigmented lesion as determined by the treating physician

5. Willing to have DermTech adhesive patch biopsies performed

6. Must be able to complete study procedures as required by the protocol

7. Willing to provide informed consent to participate in this trial

Exclusion Criteria

1. Require a surgical biopsy or excision of the lesion of interest prior to the DermTech non-invasive patch biopsy(ies)

2. Has an ulcerated or bleeding lesion that could confound the biopsy results

3. Has a suspicious lesion(s) in an area that was previously surgically biopsied

4. Has a lesion that is classified as "clinically" evident melanoma appropriate for excision

5. The lesion to be sampled is on the mucosal surface, palmoplantar surface or other area where adhesive patch biopsies cannot be performed

6. Has a known sensitivity to adhesive patches

7. Any significant medical condition that would indicate an unreasonable risk to the patient or potential interference with the study

8. Lesion is in a location were sufficient removal of non-vellus hair cannot be achieved (e.g., scalp)

9. Suspected non-melanoma skin cancer

10. Patients with contraindication(s) to surgical biopsy

Gender Eligibility: All

Minimum Age: 21 Years

Maximum Age: N/A

Investigator Details

  • Lead Sponsor
    • DermTech
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • James Rock, Study Director, DermTech
  • Overall Contact(s)
    • James Rock, 8582052736, jrock@dermtech.com

Citations Reporting on Results

Yao Z, Allen T, Oakley M, Samons C, Garrison D, Jansen B. Analytical Characteristics of a Noninvasive Gene Expression Assay for Pigmented Skin Lesions. Assay Drug Dev Technol. 2016 Aug;14(6):355-63. doi: 10.1089/adt.2016.724.

Gerami P, Yao Z, Polsky D, Jansen B, Busam K, Ho J, Martini M, Ferris LK. Development and validation of a noninvasive 2-gene molecular assay for cutaneous melanoma. J Am Acad Dermatol. 2017 Jan;76(1):114-120.e2. doi: 10.1016/j.jaad.2016.07.038. Epub 2016 Oct 1.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.